Venlafaxine
|
Product
|
Venlafaxine
|
|
Pharmaceutical Form
|
Capsules
|
|
Strengths
|
37,5 mg, 75 mg and 150 mg
|
|
Release Characteristics
|
Sustained Release (like Wyeth - UK - EFEXOR 150 mg XL capsules)
|
|
Posology
|
Once daily
|
|
Raw Material
|
DMF available
|
|
Chemical Pharmaceutical Dossier
|
Available in CTD format
|
|
Parmacokinetics
|
Available, carried out by Farmovs-Parexel (South Africa): Single dose under fasting conditions, Single dose under fed conditions, Multiple dose under fasting conditions on 42 healthy volunteers vs. Wyeth’s (UK) EFEXOR XL 150 mg capsules. Single dose under fasting conditions, single dose under fed conditions, on 32 healthy volunteers vs. Wyeth’s (France) Effexor LP 37,5 mg and 75 mg capsules
|
|
Registration underway
|
Colombia, Egypt, New Zealand, Poland, Republic of South Africa, Romania, The Netherlands, Turkey, Venezuela
|
|
Marketing
|
Croatia, Greece, Spain, South Korea, United Kingdom
|
|
Notes
|
A patent of the formulation has been filed in the major countries all over the world.
|
|
|